The Pressor Effect of Phenylpropanolamine-Reply
暂无分享,去创建一个
In Reply. — The argument by Drs Pentel and O'Connell states that variability in the response to PPA—especially at higher doses than used in our study— may be associated with a sharp increase in blood pressure in certain individuals. Unfortunately, this conclusion is based on an inadequate sample size. The study by Pentel et al 1 used a crossover design involving 10 healthy subjects and reported 3 (30%) of 10 cases with an increase of at least 20 mm Hg in systolic blood pressure for PPA vs placebo. Similarly, O'Connell et al 2 found such increases in 4 (40%) of 10 cases. The two-sided 95% confidence intervals for these proportions are 7% to 67% for the study by Pentel et al and 11% to 75% for the study by O'Connell et al. Thus, we are uncertain whether this large variation is a true biologic difference in the response to PPA
[1] M. O’Connell,et al. Individual variability in the blood pressure response to intravenous phenylpropanolamine: A pharmacokinetic and pharmacodynamic investigation , 1989, Clinical pharmacology and therapeutics.
[2] E. C. Stein,et al. Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification , 1986, Clinical pharmacology and therapeutics.
[3] R. Asinger,et al. Propranolol antagonism of phenylpropanolamine‐induced hypertension , 1985, Clinical pharmacology and therapeutics.